Business Sustainability Research Paper

Pages: 14 (3768 words)  ·  Style: Harvard  ·  Bibliography Sources: ≈ 24  ·  File: .docx  ·  Level: Doctorate  ·  Topic: Medicine

¶ … Strategic Multilateral Partnerships Help Address the Limitations of Access to Essential Medicines in Emerging Markets?

The Case of Anti-Malarial Drugs in Nigeria.

Business Case Background

The Company Challenge


Business Case Analysis

Wider Sustainability Context

Conceptual framework

Stakeholders and Community interest

Challenges for the Organization

Critical Analysis of Data Collected

Business Case Background

The organization known as Cure Pharmaceutical belongs to the pharmaceutical industry's drug delivery technology sector. A specific technology, designed by the firm, enables patients to effectively take medications without requiring water in the process. This patented Oral Thin Film technology (OTF) is small, light, and occupies much less space after packaging. Cure Pharmaceutical's innovative technology allows both easy transport and more convenient dosage forms of essential medications.

A 'for-profit' organization, Cure Pharmaceutical's source of income comes from developmental and humanitarian outcomes. The emerging markets and developing world are key targets. The firm's interests lie in initiating opportunities for business that profit both Cure Pharmaceuticals and the local communities. Its unique drug delivery methods and culturally suitable packaging makes offered medications more affordable, appealing, convenient, and safe.

Buy full Download Microsoft Word File paper
for $19.77
1.1. The Company Challenge

Research Paper on Business Sustainability Assignment

The challenge incorporates development of a sustainable model for distribution through partnerships, which enables the corporation to access developing countries more swiftly and effectively. Cure's business model is to distribute essential medications such as its Oral Thin Film (OTF) pediatric malaria treatment to emerging markets in sub-Sahara Africa. Some barriers include distribution, government regulations, country regulatory compliance, educational gap (because it is connected with healthcare), fractured supply chain and distribution channels, and social unrest (Kremer, 2002).

As the Chief Executive Officer I have been tasked with analyzing the current distribution climate as well as presenting a plan of action to our board of directors. Cure has entered into the emerging market with its oral rehydration therapy technology in Ghana. This distribution was through a third party license distribution model and was rife with difficulties. It is Cure's experience that these basic license distribution models do not effectively navigate the barrier to entry in third world countries. The main research question posed in this paper is as follows: How can Cure Pharmaceutical navigate the barriers to entry into Nigera? This includes efficacious distribution of essential medications to emerging markets, through sustainable collaborative partnership between Cure, government bodies, and community enterprises (multilateral partnership) within Nigeria?

1.2. Opportunities

Millions of individuals in developing countries cannot access essential medicines necessary for sustaining well-being and life (Kremer, 2002). Cure Pharmaceuticals views these issues as mutable health issues having achievable solutions. Such solutions will deliver social and health benefits to individuals from developing countries, while creating a profitable international business for the firm. Emphasis lies on developing non-pharmaceutical and pharmaceutical drug delivery opportunities suited to every environmental condition, in addition to developing a business prototype that fosters sustainability by way of self-respect and entrepreneurship.

2. Business Case Analysis

2.1. Wider Sustainability Context

Many individuals from developing countries do not have access to, or receive pharmaceutical assistance that could be beneficial to their well-being. The failure of anti-retroviral therapy (for HIV / AIDS) to be more widely distributed in developing nations has drawn extensive publicity. However, this is not the only case. Even far cheaper medications that can readily be delivered aren't reaching the numerous individuals who require them. Over a fourth of children all over the world, and more than half of the children in a few nations, fail to receive vaccines. This comes under the World Health Organization's (WHO) Expanded Program on Immunization. Apparently, though these vaccines cost only a few pennies per dose and do not require diagnosis and/or expensive medical intervention, the failure of vaccinations annually results in three million deaths (World Bank, 2001a). Cure has experienced precisely this issue of deliverability with the launch of their cost effective Oral Rehydration Therapy OTF technology in Ghana through a license distribution model. The distribution of the technology was stymied both by the lack of an ongoing relationship with the government of Ghana, and by the limited financial resources dedicated to this project by the (local) distributor. Cure's challenge is to develop a multilateral partnership that encompasses both government and community enterprises in Nigeria to better navigate these obstacles.

2.1.1 Resource Availability

Often, developing countries just follow developed countries' approval decisions instead of carrying out their own calculations on risk-benefit. While this approach may, in some instances, be appropriate, it might also prove to be an obstacle to adopting essential vaccines and drugs. Rotavirus, for example, kills 0.75 million children per annum in undeveloped nations; in contrast, within the United States (U.S.), rotavirus is a relatively minor health nuisance resulting in childhood diarrhea (up to 3 million cases annually). Whereas the rotavirus can be fatal without treatment, in the U.S. there are hardly any losses of life (CVI, 1999; Murphy et al., 2001a).

Many pharmaceutical companies in third world countries do not have either the financial or research capabilities to develop their own drugs. Drawing from Cure's experience in the country of Ghana, these countries have few clinical resources to develop and clinically validate new drugs. The Ghana regulatory agencies relied wholly on the regulatory approval process of the United States Food and Drug administration. The absence of a specific national regulatory process in some countries becomes a major entry barrier for pharmaceutical companies, particularly where the goal is to distribute novel essential medicines in these emerging markets. It is extremely difficult to develop a protocol in the U.S.A. For a disease state that is not prevalent in that region. Because of these underlying issues with our license distribution model in Ghana, the rehydration therapy has taken three years to gain regulatory approval. Companies who have initiated multilateral partnerships, such as the Novartis Arogya Parivar scheme and the Accelerating Access Initiative (founded by Roche), are successful examples of pharmaceutical firms pooling all the available resources to ensure quality, regulatory access, minimizing the costs involved, and establishing distribution routes (Weyzig, 2004).

2.1.3 Environmental Impact

A considerably different 'disease environment' is faced by developing countries as compared with developed countries, as a result of their geography, cultural aspects, and relative economic state of poverty. Comparison of the burdens of various diseases can be carried out across nations by employing the Disability Adjusted Life Years (DALYs) concept (Murray and Lopez, 1996). This concept considers not just deaths due to disease; it also considers the years of disability brought about from the disease. The focus of Cure in the development of a pediatric malaria treatment for Nigeria can benefit from partnering with an organization of origin that truly comprehends the impact that these diseases have both culturally and environmentally.

For example, Novartis, through its multilateral partnership, called the Arogya Parivar scheme, was successful in implementing its approach through its partnering with health educators and clinics within the rural areas of India (Ionescu-Somers, 2015). In comparison, Cure's license distribution model in Ghana was wholly reliant on feedback from the distributor. The distributor lacked the core competency and scope to educate the community about the overall impact of the disease. As well, many individuals have differential views on the severity of various endemic diseases within their own community. Collaborative outreach within any partnership and public health awareness is needed to narrow the gap.

2.2 Conceptual Framework

The primary objectives of national pharmaceutical guidelines and public sector drugs supply systems incorporate providing access to essential supplies and medicines, promoting rational consumption of medication, and ensuring efficacy, quality, and safety of medicines. This aligns with Cure Pharmaceuticals overall objectives and mission statement. To better comprehend how a multilateral partnership model comprised of Cure, government, and community enterprise can help to successfully distribute pediatric malaria medication in Nigeria, we must delve into a comparative analysis of Cure's past model in Ghana vs. that of a successful multilateral partnership model attaining successful participation in the medicine management cycle (Pharmaceutical Supply Strategies, 2012). The Novartis Arogya Parivar Scheme was chosen as a case analysis because of its overall sustainability and known success in the dissemination of essential medicines in India and other emerging markets.

Arogya Parivar, an Indian social enterprise, addresses problems in the health sector among the poor people in rural areas of India. This model came into being as a joint venture of Novartis' Consumer Health, the government of India, and another pharmaceutical company, Sandoz, in the year 2006. The pilot projects were carried out modestly in two Indian states- Maharashtra and Uttar Pradesh. Today it has affected the lives and health of over twenty five million people spread across seven Indian States (Chamania, 2010). Health educators are recruited locally and given training so that they can assist to increase awareness concerning illnesses and preventive health. Health supervisors help make sure that there is countrywide availability of medicines. Through the expansion of access to health care, the enterprise is working to ensure that Indians in the remotest of places can have access to health care (Center for Health Market Innovations, 2007). The concepts driving the Arogya Parivar program are… [END OF PREVIEW] . . . READ MORE

Two Ordering Options:

Which Option Should I Choose?
1.  Buy full paper (14 pages)Download Microsoft Word File

Download the perfectly formatted MS Word file!

- or -

2.  Write a NEW paper for me!✍🏻

We'll follow your exact instructions!
Chat with the writer 24/7.

Business Plan for the Farmery Business Plan

Business Plan for Organic Fertilizer Business Plan

Business Plan for an Imaginary Software Company Business Plan

Business Environment There Are Differing Views Term Paper

Social Environmental Sustainability Essay

View 200+ other related papers  >>

How to Cite "Business Sustainability" Research Paper in a Bibliography:

APA Style

Business Sustainability.  (2015, July 31).  Retrieved September 25, 2020, from

MLA Format

"Business Sustainability."  31 July 2015.  Web.  25 September 2020. <>.

Chicago Style

"Business Sustainability."  July 31, 2015.  Accessed September 25, 2020.